0.85Open0.50Pre Close13 Volume528 Open Interest3.00Strike Price1.21KTurnover377.32%IV8.89%PremiumDec 20, 2024Expiry Date0.75Intrinsic Value100Multiplier6DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.6445Delta0.3502Gamma2.37Leverage Ratio-0.0354Theta-0.0003Rho-1.53Eff Leverage0.0011Vega
Esperion Therapeutics Stock Discussion
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
No comment yet